Hana Pharm. Co., Ltd. Logo

Hana Pharm. Co., Ltd.

A pharmaceutical company specializing in anesthetics and narcotic analgesics.

293480 | KO

Overview

Corporate Details

ISIN(s):
KR7293480000
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 제약단지로 13-39, 화성시

Description

Hana Pharm. Co., Ltd. is a pharmaceutical company engaged in the development, manufacturing, and distribution of a wide range of medical products. The company specializes in anesthetics and narcotic analgesics, establishing a strong position in these therapeutic areas. Its portfolio also encompasses generic drugs, active pharmaceutical ingredients (APIs), antiemetics, and antibiotics. Focused on innovation, Hana Pharm's research and development pipeline includes novel drugs targeting the nervous system. Key projects under development are Byfavo Inj. (remimazolam), an ultra-short-acting anesthetic and sedative, and a new multi-functional MRI contrast agent. The company serves a global market and is expanding its capacity for injectable medicines to meet growing demand.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2019-10-10 00:00
신탁계약에의한취득상황보고서
Korean 31.1 KB
2019-09-30 00:00
기타안내사항(안내공시)
Korean 5.1 KB
2019-08-30 00:00
최대주주등소유주식변동신고서
Korean 43.9 KB
2019-08-19 00:00
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 28.1 KB
2019-08-14 00:00
반기보고서 (2019.06)
Korean 1.1 MB
2019-08-09 00:00
최대주주등소유주식변동신고서
Korean 42.9 KB
2019-08-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.1 KB
2019-08-07 00:00
최대주주등소유주식변동신고서
Korean 40.7 KB
2019-08-06 00:00
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 28.1 KB
2019-07-26 00:00
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 28.0 KB
2019-07-22 00:00
임시주주총회결과
Korean 9.0 KB
2019-07-09 00:00
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 27.3 KB
2019-07-05 00:00
주주총회소집공고
Korean 87.3 KB
2019-07-01 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.1 KB
2019-06-20 00:00
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 24.2 KB

Automate Your Workflow. Get a real-time feed of all Hana Pharm. Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hana Pharm. Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hana Pharm. Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.